Co-amorphous substance of mesalazine and arginine as well as preparation method and application of co-amorphous substance
The invention relates to a co-amorphous substance of mesalazine and arginine or a pharmaceutically acceptable salt thereof, mesalazine and arginine are combined through a non-covalent bond to form the co-amorphous substance, the co-amorphous substance is in a solid state, and the molar ratio of mesalazine to arginine is 1: 5-5: 1, or 1: 3-3: 1, 1: 2-2: 1, or 1: 2, 1: 1 or 2: 1. The co-amorphous substance of mesalazine and arginine can be used for preventing or treating enteritis, spinal arthritis, hyperuricemia or gout diseases and complications thereof..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 07. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
XIE YIFEI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-11-07, Last update posted on www.tib.eu: 2024-01-29, Last updated: 2024-02-02 |
|---|
| Patentnummer: |
CN116999447 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA019106025 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA019106025 | ||
| 003 | DE-627 | ||
| 005 | 20240202090230.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240202s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA019106025 | ||
| 035 | |a (EPA)CN116999447 | ||
| 035 | |a (EPA)88566038 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a XIE YIFEI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Co-amorphous substance of mesalazine and arginine as well as preparation method and application of co-amorphous substance |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-11-07, Last update posted on www.tib.eu: 2024-01-29, Last updated: 2024-02-02 | ||
| 520 | |a The invention relates to a co-amorphous substance of mesalazine and arginine or a pharmaceutically acceptable salt thereof, mesalazine and arginine are combined through a non-covalent bond to form the co-amorphous substance, the co-amorphous substance is in a solid state, and the molar ratio of mesalazine to arginine is 1: 5-5: 1, or 1: 3-3: 1, 1: 2-2: 1, or 1: 2, 1: 1 or 2: 1. The co-amorphous substance of mesalazine and arginine can be used for preventing or treating enteritis, spinal arthritis, hyperuricemia or gout diseases and complications thereof. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a ZHANG WEN |4 aut | |
| 700 | 0 | |a DU LIDA |4 aut | |
| 700 | 0 | |a LYU YANG |4 aut | |
| 700 | 0 | |a YANG SHIYING |4 aut | |
| 700 | 0 | |a ZHOU QIMENG |4 aut | |
| 700 | 0 | |a YUE YISONG |4 aut | |
| 700 | 0 | |a BI YANCAI |4 aut | |
| 700 | 0 | |a SU BIN |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 07. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:07 |g month:11 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/88566038/publication/CN116999447A1?q=CN116999447 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 07 |c 11 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 07 |c 11 | ||